Back

Electrocardiographic markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy (2) Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Florian Buehning

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

3 More presentations in this session

Presentation thumbnail
Associated phenotypes of pathogenic CACNA1C variants in a large cohort of patients undergoing genetic testing
Doctor M. Brogger (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Early and late changes in right heart echocardiographic parameters in hypertrophic cardiomyopathy patients after transvenous cardiac device implantation.
Miss C. Grealy (London, GB)
Abstract Slides Video
Presentation thumbnail
Overcoming sudden cardiac death and heading towards progressive heart failure: Insights from a hypertrophic cardiomyopathy referral-center cohort
Doctor A. Papageorgiou (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten
thumbnail
Congress Presentation
Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources